Anand SS - Search Results

1

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.

Eikelboom JW, Jolly SS, Belley-Cote EP, Whitlock RP, Rangarajan S, Xu L, Heenan L, Bangdiwala SI, Luz Diaz M, Diaz R, Yusufali A, Kumar Sharma S, Tarhuni WM, Hassany M, Avezum A, Harper W, Wasserman S, Almas A, Drapkina O, Felix C, Lopes RD, Berwanger O, Lopez-Jaramillo P, Anand SS, Bosch J, Choudhri S, Farkouh ME, Loeb M, Yusuf S. Eikelboom JW, et al. Among authors: anand ss. Lancet Respir Med. 2022 Dec;10(12):1169-1177. doi: 10.1016/S2213-2600(22)00298-3. Epub 2022 Oct 10. Lancet Respir Med. 2022. PMID: 36228641 Free PMC article. Clinical Trial.

2

Pharmacological treatment for myocardial infarction Part 2: Implications of clinical trials of other adjunctive therapies.

Avezum A Jr, Pais P, Flather MD, Anand S, Yusuf S. Avezum A Jr, et al. Indian Heart J. 1995 Mar-Apr;47(2):95-105. Indian Heart J. 1995. PMID: 7590849 Review. No abstract available.

3

Cost of prevention. The case of lipid lowering.

Yusuf S, Anand S. Yusuf S, et al. Circulation. 1996 May 15;93(10):1774-6. doi: 10.1161/01.cir.93.10.1774. Circulation. 1996. PMID: 8635252 No abstract available.

4

Treatment for acute myocardial infarction. Overview of randomized clinical trials.

Yusuf S, Anand S, Avezum A Jr, Flather M, Coutinho M. Yusuf S, et al. Eur Heart J. 1996 Dec;17 Suppl F:16-29. doi: 10.1093/eurheartj/17.suppl_f.16. Eur Heart J. 1996. PMID: 8960444 Review.

5

Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths.

Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S. Sheth T, et al. CMAJ. 1999 Jul 27;161(2):132-8. CMAJ. 1999. PMID: 10439820 Free PMC article.

6

Cardiovascular diseases in ethnic groups.

Anand S, Yusuf S. Anand S, et al. Can J Cardiol. 1999 Dec;15 Suppl G:47G-50G. Can J Cardiol. 1999. PMID: 10692658 No abstract available.

7

Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization.

Yusuf S, Reddy S, Ounpuu S, Anand S. Yusuf S, et al. Circulation. 2001 Nov 27;104(22):2746-53. doi: 10.1161/hc4601.099487. Circulation. 2001. PMID: 11723030 Review.

8

Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies.

Yusuf S, Reddy S, Ounpuu S, Anand S. Yusuf S, et al. Circulation. 2001 Dec 4;104(23):2855-64. doi: 10.1161/hc4701.099488. Circulation. 2001. PMID: 11733407

9

Diagnostic strategies to detect glucose intolerance in a multiethnic population.

Anand SS, Razak F, Vuksan V, Gerstein HC, Malmberg K, Yi Q, Teo KK, Yusuf S. Anand SS, et al. Diabetes Care. 2003 Feb;26(2):290-6. doi: 10.2337/diacare.26.2.290. Diabetes Care. 2003. PMID: 12547851

10

Oral anticoagulants in patients with coronary artery disease.

Anand SS, Yusuf S. Anand SS, et al. J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):62S-69S. doi: 10.1016/s0735-1097(02)02776-6. J Am Coll Cardiol. 2003. PMID: 12644343 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

468 results

Search Page